Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 2:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 224 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Severe Asthma Clear all
Completed Phase 3 Interventional Results available

A Study of the Safety and Effectiveness of Benralizumab to Treat Patients With Severe Uncontrolled Asthma.

NCT03170271
View directory record Official record
Conditions
Asthma
Interventions
Benralizumab (Medi-563), Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
100
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 87 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Jun 26, 2026, 2:32 AM EDT
Completed Phase 2 Interventional Results available

A Study to Establish the Efficacy of QBX258 in Patients With Moderate to Severe Asthma

NCT01479595
View directory record Official record
Conditions
Asthma
Interventions
QBX258, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
15
States / cities
Anaheim, California • Riverside, California • Rolling Hills Estates, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2016 · Synced Jun 26, 2026, 2:32 AM EDT
Completed Phase 1Phase 2 Interventional

Project 2 Airway Potential Hydrogen (pH) in Asthma

NCT03617718
View directory record Official record
Conditions
Cystic Fibrosis, Asthma, Severe Persistent Asthma, Healthy
Interventions
Glycine Buffer
Drug
Lead sponsor
Case Western Reserve University
Other
Eligibility
18 Years to 50 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
2
States / cities
Indianapolis, Indiana • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Jun 26, 2026, 2:32 AM EDT
Terminated Phase 2 Interventional Results available

Pilot Study of Pioglitazone for the Treatment of Moderate to Severe Asthma in Obese Asthmatics (Glitz Asthma)

NCT00787644
View directory record Official record
Conditions
Asthma, Obesity
Interventions
Pioglitazone, Placebo
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Colchester, Vermont
Source: ClinicalTrials.gov public record
Updated Feb 25, 2015 · Synced Jun 26, 2026, 2:32 AM EDT
Completed Not applicable Interventional

Effectiveness and Cost Study Comparing Two Ways to Deliver Albuterol for the Treatment of Asthma in the Hospital

NCT00623688
View directory record Official record
Conditions
Status Asthmaticus
Interventions
Metered Dose Inhaler & Optichamber Advantage Valve Holding Chamber (VHC), Airlife Sidestream High Efficiency Nebulizer
Device
Lead sponsor
Akron Children's Hospital
Other
Eligibility
12 Months to 18 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 13, 2015 · Synced Jun 26, 2026, 2:32 AM EDT
Completed Phase 2 Interventional

A Study of Lebrikizumab (RO5490255) in Participants With Severe Oral Corticosteroids (OCS) Dependent Asthma

NCT01987492
View directory record Official record
Conditions
Asthma
Interventions
Lebrikizumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years to 75 Years
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
9
States / cities
Bakersfield, California • Long Beach, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated May 21, 2017 · Synced Jun 26, 2026, 2:32 AM EDT
Completed Phase 3 Interventional Results available

Placebo-controlled Efficacy and Safety Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype

NCT04719832
View directory record Official record
Conditions
Asthma
Interventions
GSK3511294 (Depemokimab), Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
30
States / cities
Encinitas, California • Long Beach, California • Pasadena, California + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2024 · Synced Jun 26, 2026, 2:32 AM EDT
Recruiting Phase 3 Interventional

Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)

NCT06191315
View directory record Official record
Conditions
Wheezing, Asthma
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
2 Years to 5 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
14
States / cities
Phoenix, Arizona • Destin, Florida • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Jun 26, 2026, 2:32 AM EDT
Completed Phase 3 Interventional

A Phase 3, Multicenter, Open-label Continuation Study in Moderate to Severe Asthmatic Subjects Who Completed FlutiForm HFA pMDI Study SKY2028-3-005

NCT00747318
View directory record Official record
Conditions
Asthma
Interventions
SKP FlutiForm HFA pMDI
Drug
Lead sponsor
SkyePharma AG
Industry
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
10
States / cities
Scottsdale, Arizona • Orange County, California • Colorado Springs, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2011 · Synced Jun 26, 2026, 2:32 AM EDT
Completed Phase 4 Interventional Results available

Treatment of Outpatients With Severe Asthma and Moderate or Severe Major Depressive Disorder

NCT00621946
View directory record Official record
Conditions
Severe Asthma, Moderate or Severe Major Depressive Disorder
Interventions
Placebo, Escitalopram
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 3, 2014 · Synced Jun 26, 2026, 2:32 AM EDT
Completed Not applicable Interventional

Electronic Monitoring of Medication Adherence in Moderate to Severe Asthma Patients

NCT02913092
View directory record Official record
Conditions
Asthma
Interventions
Electronic sensor and OW education
Behavioral
Lead sponsor
Montefiore Medical Center
Other
Eligibility
5 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 21, 2022 · Synced Jun 26, 2026, 2:32 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Tezepelumab in Adults & Adolescents With Severe Uncontrolled Asthma

NCT03347279
View directory record Official record
Conditions
Asthma
Interventions
Experimental: Tezepelumab, Placebo
Biological · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 80 Years
Enrollment
1,061 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
95
States / cities
Dothan, Alabama • Foley, Alabama • Gilbert, Arizona + 79 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2021 · Synced Jun 26, 2026, 2:32 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of 2 Doses of Tiotropium Respimat Compared to Placebo in Adolescents With Severe Persistent Asthma

NCT01277523
View directory record Official record
Conditions
Asthma
Interventions
tiotropium high dose, placebo, tiotropium low dose
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
12 Years to 17 Years
Enrollment
392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
8
States / cities
Stockton, California • Normal, Illinois • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2014 · Synced Jun 26, 2026, 2:32 AM EDT
Completed Phase 2 Interventional Results available

4 Week 2 Way Crossover Double Blind Treatment Phase With Combivent CFC Versus Albuterol Followed by a 4 Week Open Label Combivent Respimat When All Drugs Are Used for Symptom Relief as Needed in Pts With Moderate to Severe Asthma

NCT00818454
View directory record Official record
Conditions
Asthma
Interventions
Combivent CFC MDI, Albuterol HFA MDI, Respimat Combivent
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
41
States / cities
Birmingham, Alabama • Los Angeles, California • Palmdale, California + 36 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Jun 26, 2026, 2:32 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Effect of Tezepelumab on the Immune Response to Influenza Vaccination in Participants With Asthma

NCT05062759
View directory record Official record
Conditions
Moderate to Severe Asthma
Interventions
Tezepelumab, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 21 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
15
States / cities
Bakersfield, California • Huntington Beach, California • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Jun 26, 2026, 2:32 AM EDT
Completed Phase 3 Interventional Results available

Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma

NCT00529529
View directory record Official record
Conditions
Asthma
Interventions
Indacaterol 300 μg, Salmeterol 50 μg, Placebo to indacaterol, Placebo to salmeterol
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
805 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
56
States / cities
Glendale, Arizona • Phoenix, Arizona • Encinitas, California + 44 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2011 · Synced Jun 26, 2026, 2:32 AM EDT
Completed Phase 4 Interventional

Longitudinal Cohort Study in Participants With Severe Asthma to Assess Biomarkers

NCT02537691
View directory record Official record
Conditions
Asthma
Interventions
FP, LABA, LTRA, LAMA, Theophylline, Oral Corticosteroids
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
483 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
29
States / cities
Birmingham, Alabama • Mission Viejo, California • Sacramento, California + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2019 · Synced Jun 26, 2026, 2:32 AM EDT
Completed Phase 3 Interventional Results available

A Study to Determine Long-term Safety of Mepolizumab in Asthmatic Subjects

NCT01842607
View directory record Official record
Conditions
Asthma
Interventions
Mepolizumab
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
651 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
20
States / cities
Long Beach, California • Newport Beach, California • Riverside, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2018 · Synced Jun 26, 2026, 2:32 AM EDT
Completed Phase 1 Interventional Results available

Vitamin D and Severe Asthma Exacerbations

NCT01921894
View directory record Official record
Conditions
Asthma
Interventions
Cholecalciferol
Dietary Supplement
Lead sponsor
University of Pittsburgh
Other
Eligibility
6 Years to 14 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Jun 26, 2026, 2:32 AM EDT
Completed Phase 2 Interventional

Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma

NCT06102005
View directory record Official record
Conditions
Asthma
Interventions
Lunsekimig, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 80 Years
Enrollment
685 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
48
States / cities
Scottsdale, Arizona • Yuma, Arizona • Lancaster, California + 41 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Jun 26, 2026, 2:32 AM EDT
Recruiting Phase 2 Interventional

A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma

NCT07323654
View directory record Official record
Conditions
Eosinophilic Asthma
Interventions
KT-621, Placebo
Drug · Other
Lead sponsor
Kymera Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
20
States / cities
Long Beach, California • Northridge, California • Redding, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Jun 26, 2026, 2:32 AM EDT
Terminated Phase 2 Interventional

CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma

NCT01673672
View directory record Official record
Conditions
Moderate to Severe Allergic Asthma
Interventions
CYT003, Placebo
Biological
Lead sponsor
Cytos Biotechnology AG
Industry
Eligibility
18 Years to 65 Years
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
21
States / cities
Los Angeles, Huntington Beach, San Jose, California • Walnut Creek, San Diego, Riverside, Fountain Valley, California • Colorado Springs, Denver, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated May 13, 2014 · Synced Jun 26, 2026, 2:32 AM EDT
Not yet recruiting Not applicable Interventional

Bilevel Positive Airway Pressure (BPAP) for Severe Asthma

NCT07582211
View directory record Official record
Conditions
Pediatric Asthma, Acute Asthma, BiPAP, Non-invasive Positive Pressure Ventilation
Interventions
Bilevel positive airway pressure ventilation
Device
Lead sponsor
Columbia University
Other
Eligibility
5 Years to 17 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
New York, New York • Columbus, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Jun 26, 2026, 2:32 AM EDT